New hope for Tough-to-Treat leukemia patients
NCT ID NCT07471841
Summary
This study is testing a drug called olutasidenib for adults with a specific type of acute myeloid leukemia (AML) that has returned or stopped responding to treatment. The goal is to see if the drug can help control the cancer and improve blood counts. About 25 people who have already tried a treatment containing venetoclax will take the study drug daily in 28-day cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.